These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 11692083)

  • 21. Effects of oral vitamin K on S- and R-warfarin pharmacokinetics and pharmacodynamics: enhanced safety of warfarin as a CYP2C9 probe.
    Kim JS; Nafziger AN; Gaedigk A; Dickmann LJ; Rettie AE; Bertino JS
    J Clin Pharmacol; 2001 Jul; 41(7):715-22. PubMed ID: 11452703
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon.
    Visser LE; van Schaik RH; van Vliet M; Trienekens PH; De Smet PA; Vulto AG; Hofman A; van Duijn CM; Stricker BH
    Thromb Haemost; 2004 Jul; 92(1):61-6. PubMed ID: 15213846
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High frequency of mutations related to impaired CYP2C9 metabolism in a Caucasian population.
    García-Martín E; Martínez C; Ladero JM; Gamito FJ; Agúndez JA
    Eur J Clin Pharmacol; 2001 Apr; 57(1):47-9. PubMed ID: 11372590
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genotypes associated with reduced activity of VKORC1 and CYP2C9 and their modification of acenocoumarol anticoagulation during the initial treatment period.
    Teichert M; van Schaik RH; Hofman A; Uitterlinden AG; de Smet PA; Stricker BH; Visser LE
    Clin Pharmacol Ther; 2009 Apr; 85(4):379-86. PubMed ID: 19225451
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Significance of cytochrome P450 2C9 genotype for the bleeding complications in patients treated with acenocoumarol].
    Márk L; Márki-Zay J; Fodor L; Kondacs A; Paragh G; Katona A
    Orv Hetil; 2005 Apr; 146(16):739-43. PubMed ID: 15889670
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reply to rebuttal: Gene variants of the cytochrome P450 CYP2C9 affect oral anticoagulation with warfarin.
    Margaglione M; Brancaccio V; Ciampa A; Di Minno G
    Thromb Haemost; 2001 Sep; 86(3):938. PubMed ID: 11583336
    [No Abstract]   [Full Text] [Related]  

  • 27. Extreme sensitivity to acenocoumarol therapy in patient with both VKORC.-1639 A/A and CYP2C9*1/*3 genotypes.
    Kovac MK; Rakicevic LB; Radojkovic DP
    J Thromb Thrombolysis; 2011 Oct; 32(3):368-71. PubMed ID: 21638223
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Warfarin therapy in a patient homozygous for the CYP2C9 3 allele.
    Ablin J; Cabili S; Lagziel A; Peretz H
    Isr Med Assoc J; 2002 Feb; 4(2):139-41. PubMed ID: 11875991
    [No Abstract]   [Full Text] [Related]  

  • 29. Altered pharmacokinetics of R- and S-acenocoumarol in a subject heterozygous for CYP2C9*3.
    Thijssen HH; Drittij MJ; Vervoort LM; de Vries-Hanje JC
    Clin Pharmacol Ther; 2001 Sep; 70(3):292-8. PubMed ID: 11557918
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic association between sensitivity to warfarin and expression of CYP2C9*3.
    Steward DJ; Haining RL; Henne KR; Davis G; Rushmore TH; Trager WF; Rettie AE
    Pharmacogenetics; 1997 Oct; 7(5):361-7. PubMed ID: 9352571
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CYP2C9 genotyping in acenocoumarol treatment: is it a cost-effective addition to international normalized ratio monitoring?
    Schalekamp T; Boink GJ; Visser LE; Stricker BH; de Boer A; Klungel OH
    Clin Pharmacol Ther; 2006 Jun; 79(6):511-20. PubMed ID: 16765138
    [No Abstract]   [Full Text] [Related]  

  • 32. The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon.
    Visser LE; van Vliet M; van Schaik RH; Kasbergen AA; De Smet PA; Vulto AG; Hofman A; van Duijn CM; Stricker BH
    Pharmacogenetics; 2004 Jan; 14(1):27-33. PubMed ID: 15128048
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement.
    van der Weide J; Steijns LS; van Weelden MJ; de Haan K
    Pharmacogenetics; 2001 Jun; 11(4):287-91. PubMed ID: 11434505
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of CYP2C9 and VKORC1 polymorphisms on warfarin and acenocoumarol in a sample of Lebanese people.
    Esmerian MO; Mitri Z; Habbal MZ; Geryess E; Zaatari G; Alam S; Skouri HN; Mahfouz RA; Taher A; Zgheib NK
    J Clin Pharmacol; 2011 Oct; 51(10):1418-28. PubMed ID: 21148049
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is cytochrome P450 2C9 genotype associated with NSAID gastric ulceration?
    Martin JH; Begg EJ; Kennedy MA; Roberts R; Barclay ML
    Br J Clin Pharmacol; 2001 Jun; 51(6):627-30. PubMed ID: 11422024
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes.
    Thijssen HH; Flinois JP; Beaune PH
    Drug Metab Dispos; 2000 Nov; 28(11):1284-90. PubMed ID: 11038154
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytochrome P450 2C9 polymorphism and acenocoumarol therapy.
    Mark L; Marki-Zay J; Fodor L; Hajdara I; Paragh G; Katona A
    Kardiol Pol; 2006 Apr; 64(4):397-402; discussion 403-4. PubMed ID: 16699986
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Frequency of cytochrome P450 2C9 mutant alleles in a Korean population.
    Yoon YR; Shon JH; Kim MK; Lim YC; Lee HR; Park JY; Cha IJ; Shin JG
    Br J Clin Pharmacol; 2001 Mar; 51(3):277-80. PubMed ID: 11298075
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overanticoagulation associated with combined use of antifungal agents and coumarin anticoagulants.
    Visser LE; Penning-van Beest FJ; Kasbergen AA; De Smet PA; Vulto AG; Hofman A; Stricker BH
    Clin Pharmacol Ther; 2002 Jun; 71(6):496-502. PubMed ID: 12087353
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status.
    Schalekamp T; Oosterhof M; van Meegen E; van Der Meer FJ; Conemans J; Hermans M; Meijerman I; de Boer A
    Clin Pharmacol Ther; 2004 Nov; 76(5):409-17. PubMed ID: 15536456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.